[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100370084":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":34,"locations":45,"responsibleParty":182,"collaborators":184,"id":197,"slug":33,"hasResults":198,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":198,"sex":204,"minAge":205,"maxAge":206,"enrollmentInfo":207,"targetDuration":33,"studyType":210,"phases":211,"briefSummary":213,"conditions":214,"keywords":220,"overallStatus":48,"whyStopped":33,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":241},{"fullName":5,"class":6},"Frantz Viral Therapeutics, LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Artesunate vaginal insert","EXPERIMENTAL","Participants will receive three 5-day cycles of artesunate vaginal inserts, 200mg\u002Fday, at week 0, week 2, week 4.",[13],"Drug: Artesunate vaginal insert",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo vaginal inserts","PLACEBO_COMPARATOR","Participants will receive three 5-day cycles of placebo vaginal inserts, at week 0, week 2, and week 4.",[19],"Drug: Placebo vaginal insert",[21,29],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Artesunate formulated as vaginal inserts, 200mg",[9],[26,27,28],"Artesunic acid","DHA","artemisinin",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Placebo vaginal insert","Placebo for artesunate vaginal inserts",[15],null,[35,41],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Mihaela Plesa, BA, CCRP","CONTACT","440-255-1155","100","FVTinfo@frantzgroup.com",{"name":42,"role":37,"phone":43,"phoneExt":33,"email":44},"Ahmad Bayat, MD","(301) 956-2523","ahmadb@amarexcro.com",[46,70,87,115,129,148,171],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Florida Gynecologic Oncology","RECRUITING","Fort Myers","Florida","33905","United States",{"type":54,"coordinates":55},"Point",[56,57],-81.84059,26.62168,{"lat":57,"lon":56},[60,64,67],{"name":61,"role":37,"phone":62,"phoneExt":33,"email":63},"Cami Hansen","239-334-6626","cami.hansen25@gmail.com",{"name":65,"role":66,"phone":33,"phoneExt":33,"email":33},"Fadi Abu Shahin, MD","PRINCIPAL_INVESTIGATOR",{"name":68,"role":69,"phone":33,"phoneExt":33,"email":33},"Samith Sandadi, MD","SUB_INVESTIGATOR",{"facility":71,"status":48,"city":72,"state":73,"zip":74,"country":52,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"University of Michigan","Ann Arbor","Michigan","48109",{"type":54,"coordinates":76},[77,78],-83.74088,42.27756,{"lat":78,"lon":77},[81,85],{"name":82,"role":37,"phone":83,"phoneExt":33,"email":84},"Mubeenah Syedah","734-998-6349","symubeen@med.umich.edu",{"name":86,"role":66,"phone":33,"phoneExt":33,"email":33},"Diane Harper, MD",{"facility":88,"status":48,"city":89,"state":90,"zip":91,"country":52,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Cleveland Clinic Fairview Hospital","Cleveland","Ohio","44111",{"type":54,"coordinates":93},[94,95],-81.69541,41.4995,{"lat":95,"lon":94},[98,102,105,107,109,111,113],{"name":99,"role":37,"phone":100,"phoneExt":33,"email":101},"Donna White","216-445-8090","whited11@ccf.org",{"name":103,"role":37,"phone":100,"phoneExt":33,"email":104},"Megan Park","parkm2@ccf.org",{"name":106,"role":66,"phone":33,"phoneExt":33,"email":33},"Chad Michener, MD",{"name":108,"role":69,"phone":33,"phoneExt":33,"email":33},"Mariam AlHilli, MD",{"name":110,"role":69,"phone":33,"phoneExt":33,"email":33},"Steven Waggonner, MD",{"name":112,"role":69,"phone":33,"phoneExt":33,"email":33},"Robert DeBernardo, MD",{"name":114,"role":69,"phone":33,"phoneExt":33,"email":33},"Roberto Vargas, MD",{"facility":116,"status":48,"city":89,"state":90,"zip":117,"country":52,"cosmosGeoPoint":118,"geoPoint":120,"contacts":121},"Cleveland Clinic Foundation","44195",{"type":54,"coordinates":119},[94,95],{"lat":95,"lon":94},[122,123,124,125,126,127,128],{"name":99,"role":37,"phone":100,"phoneExt":33,"email":101},{"name":103,"role":37,"phone":100,"phoneExt":33,"email":104},{"name":106,"role":66,"phone":33,"phoneExt":33,"email":33},{"name":108,"role":69,"phone":33,"phoneExt":33,"email":33},{"name":110,"role":69,"phone":33,"phoneExt":33,"email":33},{"name":112,"role":69,"phone":33,"phoneExt":33,"email":33},{"name":114,"role":69,"phone":33,"phoneExt":33,"email":33},{"facility":130,"status":48,"city":131,"state":90,"zip":132,"country":52,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"Hillcrest Hospital","Mayfield Heights","44124",{"type":54,"coordinates":134},[135,136],-81.4579,41.51922,{"lat":136,"lon":135},[139,140,141,142,143,144,145,146],{"name":99,"role":37,"phone":100,"phoneExt":33,"email":101},{"name":103,"role":37,"phone":100,"phoneExt":33,"email":104},{"name":106,"role":66,"phone":33,"phoneExt":33,"email":33},{"name":108,"role":69,"phone":33,"phoneExt":33,"email":33},{"name":110,"role":69,"phone":33,"phoneExt":33,"email":33},{"name":112,"role":69,"phone":33,"phoneExt":33,"email":33},{"name":114,"role":69,"phone":33,"phoneExt":33,"email":33},{"name":147,"role":69,"phone":33,"phoneExt":33,"email":33},"Lindsey Beffa, MD",{"facility":149,"status":48,"city":150,"state":151,"zip":152,"country":52,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"The Harris Health System (L.B.J Hospital)","Houston","Texas","77026",{"type":54,"coordinates":154},[155,156],-95.36327,29.76328,{"lat":156,"lon":155},[159,163,167,169],{"name":160,"role":37,"phone":161,"phoneExt":33,"email":162},"Jessica Gallegos","713-563-4580","jrgalleg@mdanderson.org",{"name":164,"role":37,"phone":165,"phoneExt":33,"email":166},"Cindy Melendez","713-563-4582","cvmelend@mdanderson.org",{"name":168,"role":66,"phone":33,"phoneExt":33,"email":33},"Andrea Milbourne, MD",{"name":170,"role":69,"phone":33,"phoneExt":33,"email":33},"Kathleen Schmeler, MD",{"facility":172,"status":48,"city":150,"state":151,"zip":173,"country":52,"cosmosGeoPoint":174,"geoPoint":176,"contacts":177},"University of Texas, M.D. Anderson","77030",{"type":54,"coordinates":175},[155,156],{"lat":156,"lon":155},[178,179,180,181],{"name":160,"role":37,"phone":161,"phoneExt":33,"email":162},{"name":164,"role":37,"phone":165,"phoneExt":33,"email":166},{"name":168,"role":66,"phone":33,"phoneExt":33,"email":33},{"name":170,"role":69,"phone":33,"phoneExt":33,"email":33},{"type":183,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR",[185,188,190,193,195,196],{"name":186,"class":187},"Amarex Clinical Research","OTHER",{"name":189,"class":187},"M.D. Anderson Cancer Center",{"name":191,"class":192},"Harris Health System (L.B.J. Hospital)","UNKNOWN",{"name":194,"class":187},"The Cleveland Clinic",{"name":71,"class":187},{"name":47,"class":192},"100370084",false,"NCT04098744","Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2\u002F3)","A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2\u002F3)","ART-CIN_IIB","Inclusion Criteria:\n\n* Adult females age ≥ 25 years\n* Capable of informed consent\n* Any HPV genotype detectable by DNA test\u002FHPV genotyping\n* Colposcopically-directed, histologically confirmed tissue diagnosis of cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2\u002F3)\n* Women of childbearing potential agree to use birth control through week17 of the study.\n* Weight ≥ 50kg\n\nExclusion Criteria:\n\n* Pregnant and nursing women\n* Active autoimmune disease\n* Taking immunosuppressive medication\n* HIV seropositivity\n* Immunocompromised subjects\n* Evidence of concurrent cervical adenocarcinoma in situ\n* Concurrent malignancy except for nonmelanoma skin lesions, because treatment for other cancers have systemic effects","FEMALE","25 Years","100 Years",{"count":208,"type":209},78,"ESTIMATED","INTERVENTIONAL",[212],"PHASE2","This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2\u002F3).",[215,216,217,218,219],"CIN 2\u002F3","HPV Infection","Pre-Cancerous Dysplasia","Cervical Dysplasia","HPV Related Disease",[221,222,223,224,225,226,227,228,28,229,230,231],"treatment study","cancer prevention","non-surgical","HPV related disease","CIN","topical treatment","vaginal inserts","artesunate","non-invasive","high risk HPV","vaginal suppository","2025-09-29",{"date":234,"type":235},"2025-10-02","ACTUAL",{"date":237,"type":235},"2020-09-09",{"date":239,"type":209},"2026-12-31",{"name":5,"class":6},7]